Division of Signal Transduction Therapy
The Division of Signal Transduction Therapy or DSTT is an organization managed by the University of Dundee, the Medical Research Council, and the pharmaceutical companies AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Serono, Janssen Pharmaceutica, and Pfizer. The purpose of the collaboration is to conduct cell signalling research and to encourage development of new drug treatments for global diseases such as cancer, rheumatoid arthritis, and Parkinson’s Disease. Specifically the collaboration aims to target protein kinases and the ubiquitylation system in the development of these therapies. It is one of the largest ever collaborations between the commercial pharmaceutical industry and any academic research institute.
primaryTopic
Division of Signal Transduction Therapy
The Division of Signal Transduction Therapy or DSTT is an organization managed by the University of Dundee, the Medical Research Council, and the pharmaceutical companies AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Serono, Janssen Pharmaceutica, and Pfizer. The purpose of the collaboration is to conduct cell signalling research and to encourage development of new drug treatments for global diseases such as cancer, rheumatoid arthritis, and Parkinson’s Disease. Specifically the collaboration aims to target protein kinases and the ubiquitylation system in the development of these therapies. It is one of the largest ever collaborations between the commercial pharmaceutical industry and any academic research institute.
has abstract
The Division of Signal Transdu ...... y academic research institute.
@en
budget ($)
formation year
number of staff
Link from a Wikipage to an external page
Wikipage page ID
27,817,581
Wikipage revision ID
683,808,302
comment
The Division of Signal Transdu ...... y academic research institute.
@en
label
Division of Signal Transduction Therapy
@en
wasDerivedFrom
homepage
isPrimaryTopicOf
name
Division of Signal Transduction Therapy
@en